Aims & Scope
The Journal of Antibodies is an open-access, peer-reviewed antibody research journal published by Directive Publications. It serves as a multidisciplinary forum for original scholarship on the structure, function, engineering, and clinical application of immunoglobulins, advancing knowledge across both basic immunology and translational antibody science.
The journal welcomes work on monoclonal and polyclonal antibodies, therapeutic antibodies and antibody-drug conjugates, single-domain antibodies and nanobodies, bispecific and engineered formats, and the autoantibodies that drive autoimmune, renal, and transplant-related disease. Coverage extends to antibody discovery and engineering, immunoassay and ligand-binding-assay development, immunochemistry, antibody-mediated graft rejection (including HLA and non-HLA antibodies), and the validation, specificity, and reproducibility of research antibodies.
We consider original research, reviews, methods papers, case reports, and editorials of interest to immunologists, biochemists, clinical and translational researchers, diagnostic laboratories, and biopharmaceutical scientists. Every submission undergoes double-blind peer review.
Accepted articles are published under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar, and our OAI-PMH endpoint. The journal follows COPE ethical principles.
Subject Coverage
Journal of Antibodies welcomes original research, reviews, and case reports across the following core areas:
Research Topics
Core subject areas published in Journal of Antibodies — explore related research across our journals.
Articles
Single-domain antibodies-biology, engineering and emerging applications
Evaluating the Clinical Relevance of Antibodies againstNon-Human Leukocyte Antigen in Kidney Transplantation
Frequently Asked Questions
What topics does the Journal of Antibodies cover?
The Journal of Antibodies covers the full breadth of immunoglobulin science: monoclonal and therapeutic antibodies, antibody engineering, single-domain antibodies and nanobodies, antibody-drug conjugates, autoantibodies and disease biomarkers, transplantation immunology (HLA and non-HLA antibodies), immunoassays and immunochemistry, and the validation and reproducibility of research antibodies.
Who should read and publish in the Journal of Antibodies?
The journal is intended for immunologists, biochemists, clinical and translational researchers, diagnostic and immunoassay laboratories, transplant scientists, and biopharmaceutical researchers working on antibody discovery, engineering, diagnostics, and therapeutics. Authors with original studies, methods, reviews, or case reports on any aspect of antibody science are encouraged to submit.
Is the Journal of Antibodies open access, and who holds copyright?
Yes. The Journal of Antibodies is fully open access. All accepted articles are published under a Creative Commons Attribution (CC-BY 4.0) licence, and authors retain copyright while permitting open reuse with attribution. Every article also receives a permanent Crossref DOI for stable citation.
What types of articles does the Journal of Antibodies accept?
The journal accepts original research articles, review articles, methods and validation papers, case reports, and editorials addressing therapeutic, diagnostic, methodological, and translational aspects of antibodies, from antibody engineering and immunoassay development to autoantibody biomarkers and research-antibody quality.
How does peer review work at the Journal of Antibodies?
Every submission to the Journal of Antibodies undergoes double-blind peer review, in which author and reviewer identities are concealed from one another. The journal follows COPE ethical principles to ensure rigorous, impartial, and ethical evaluation of antibody research.
Is there an article-processing charge, and are waivers available?
As an open-access antibody research journal, the Journal of Antibodies applies an article-processing charge on acceptance to sustain open dissemination. Waivers and discounts are available; authors should contact the editorial office regarding the current charge and eligibility before or at submission.
How can I submit my antibody research to the journal?
Authors can submit through the journal's submit page after preparing their manuscript per the author guidelines. The Journal of Antibodies welcomes submissions on monoclonal and therapeutic antibodies, autoantibodies, antibody engineering, immunoassays, and antibody validation, and provides a permanent Crossref DOI and global discoverability for every accepted article.
Where is content from the Journal of Antibodies discoverable?
Articles are assigned Crossref DOIs and are discoverable via OpenAlex and Google Scholar, with full metadata exposed through an OAI-PMH endpoint for harvesting. As a new open-access publisher, Directive Publications is also working toward additional indexing such as DOAJ eligibility.